Copyright
©The Author(s) 2025.
World J Cardiol. May 26, 2025; 17(5): 105670
Published online May 26, 2025. doi: 10.4330/wjc.v17.i5.105670
Published online May 26, 2025. doi: 10.4330/wjc.v17.i5.105670
Table 1 Clinical information for the patient in this report
The first hospitalization before PTX (January 2020) | The second hospitalization before PTX (July 2021) | After PTX (May 2023) | |
Left ventricular ejection fraction (%) | 13 | 22 | 53 |
Left ventricular end-diastolic diameter (mm) | 65 | 65 | 47 |
Right ventricle (mm) | 29 | 26 | 20 |
Left atrium (mm) | 42 | 44 | 36 |
Right atrium (mm) | 53 × 49 | 52 × 44 | 44 × 37 |
Parathyroid hormone (pg/mL) | 206 | 284 | 56.4 |
Brain natriuretic peptide (pg/mL) | 2555.5 | 2583.9 | |
Corrected calcium(mmol/L) | 2.85 | 2.78 | 2.44 |
Phosphate (mmol/L) | 1.17 | 0.95 | |
Creatinine (μmol/L) | 160.7 | 210.4 | 171.2 |
Estimated glomerular filtration rate (mL/minute) | 42.4 | 30.2 | 38.2 |
- Citation: Jiang W, Qiu YZ, Xi HT, Ma HH, Wu X, Yuan XM, Wang WY, Kong H, Li XP. Reversible dilated cardiomyopathy caused by primary hyperparathyroidism: A case report. World J Cardiol 2025; 17(5): 105670
- URL: https://www.wjgnet.com/1949-8462/full/v17/i5/105670.htm
- DOI: https://dx.doi.org/10.4330/wjc.v17.i5.105670